The book covers very recent research that promises to revolutionize cancer-directed chemotherapeutic interventions

The book provides a unique translational coverage between molecular cancer biology and cancer-directed therapeutic development

The book provides state-of-the-art coverage written by recognized experts from five continents

Includes supplementary material: [...]

Preface.- Introduction to cell stress responses in cancer: The big picture.- DNA repair dysregulation in cancer: From molecular mechanisms to synthetic-lethal opportunities.- Cell cycle checkpoint defects as anticancer targets: From molecular mechanisms to therapeutic opportunities.- p53 at the crossroads between stress response signaling and tumorigenesis: From molecular mechanisms to therapeutic opportunities.- Sirtuins as a double-edged sword in cancer: From molecular mechanisms to therapeutic opportunities.- MicroRNA regulated stress responses in cancer.- Senescence in oncogenesis: From molecular mechanisms to therapeutic opportunities.- Pro-senescence therapy for cancer: time for the clinic.- Integrating proteotoxic stress response pathways for induction of cell death in cancer cells: molecular mechanisms and opportunities.- The Hsp70 family of heat shock proteins in tumorigenesis: From molecular mechanisms to therapeutic opportunities.- The ubiquitin-proteasome system (UPS) as a cancer drug target: Emerging mechanisms and therapeutics.- Endoplasmatic reticulum stress in multiple myeloma: From molecular mechanisms to therapeutic opportunities.- Melanomagenic gene alterations viewed from a redox perspective: Molecular mechanisms and therapeutic opportunities.- Targeting hypoxic adaptations of cancer cells: Molecular mechanisms and therapeutic opportunities.- Targeting glycolytic adaptations of cancer cells: from molecular mechanisms to therapeutic opportunities.- At the crossroads between mitochondrial metabolite transport and apoptosis: VDAC1 as an emerging cancer drug target.- Inflammatory dysregulation and cancer: From molecular mechanisms to therapeutic opportunities.- Cell-nonautonomous ER stress-mediated dysregulation of immunity by cancer cells.- Index.